KEEN EYE is a health tech company, building machine learning technology for translational and clinical research, with a particular focus and a ‘keen expertise’ on imaging data. Thanks to its technology, KEEN EYE allows doctors and biologists to reproduce and extend their visual expertise, notably by identifying signals with high predictive value that are yet difficult to detect by eye. They save valuable time in day-to-day decision-making, whether it is to diagnose, screen disease, or evaluate the effectiveness of a drug, in a more precise and standardized way.

KEEN EYE is a health tech company, building machine learning technology for translational and clinical research, with a particular focus and a ‘keen expertise’ on imaging data. Thanks to its technology, KEEN EYE allows doctors and biologists to reproduce and extend their visual expertise, notably by identifying signals with high predictive value that are yet difficult to detect by eye. They save valuable time in day-to-day decision-making, whether it is to diagnose, screen disease, or evaluate the effectiveness of a drug, in a more precise and standardized way.

EyeArt is the first and only FDA-cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.It is proven to be safe, fast, and consistent.